 |
53 Diseases |  |
490 Trials |
|
490 Trials |  |
8927 News |  |
| «12...345678910111213...123124» |
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: New Small-Molecule SERCA Inhibitors Enhance Treatment Efficacy in Lenvatinib-Resistant Papillary Thyroid Cancer. (Pubmed Central) - Oct 16, 2024
These candidates demonstrated significant tumor shrinkage in a xenograft tumor model and reduced cell viability in patient-derived lenvatinib-resistant PTC cells when used in combination with lenvatinib. Our findings have potential clinical value for the development of new combination therapies to effectively target highly malignant, anticancer drug-resistant cancers.
- ||| Enrollment open, Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Monotherapy: Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98) (clinicaltrials.gov) - Oct 16, 2024
P1/2, N=110, Recruiting, Sponsor: Merck Sharp & Dohme LLC
Our findings have potential clinical value for the development of new combination therapies to effectively target highly malignant, anticancer drug-resistant cancers. Active, not recruiting --> Recruiting | N=80 --> 110 | Trial completion date: Nov 2026 --> Nov 2029 | Trial primary completion date: Nov 2026 --> May 2026
- | Enweida (envafolimab) / 3DMed, Ascletis, Lenvima (lenvatinib) / Eisai, Merck (MSD)
New trial, Surgery: D-TACE-HAIC Combined With Envafolimab and Lenvatinib in the Treatment of Unresectable Intrahepatic Cholangiocarcinoma: a Prospective, Single-arm, Phase II Clinical Study (clinicaltrials.gov) - Oct 16, 2024
P=N/A, N=37, Recruiting, Sponsor: Fujian Provincial Hospital
- | Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
Journal: Prognostic Significance of Psoas Muscle Index in Unresectable Hepatocellular Carcinoma: Comparative Analysis of Lenvatinib and Atezolizumab Plus Bevacizumab. (Pubmed Central) - Oct 16, 2024
A low PMI emerges as a significant prognostic factor in uHCC patients undergoing drug therapy, not only in LEN therapy but also in ATZ-BEV therapy. Additionally, ATZ-BEV therapy may be more favorable for sarcopenic patients with advanced HCC stages.
- | Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal, Metastases: Lenvatinib Plus Pembrolizumab versus Doxorubicin for Advanced or Recurrent Endometrial Cancer with Short Treatment-Free Intervals Following First-Line Carboplatin Plus Paclitaxel. (Pubmed Central) - Oct 16, 2024
Regarding adverse event analysis, a higher incidence of hypothyroidism and proteinuria was observed with lenvatinib plus pembrolizumab, and more hematological toxicities were observed with doxorubicin. in patients with treatment-free intervals of <6 months, lenvatinib plus pembrolizumab still confers improved survival compared with doxorubicin in PT-treated, advanced, or recurrent ECs.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal, Metastases: Genomic landscape and clinical features of advanced thyroid carcinoma: a national database study in Japan. (Pubmed Central) - Oct 15, 2024
TP53 abnormality was an independent poor prognostic factor for overall survival in differentiated thyroid carcinoma. The time to treatment failure for lenvatinib was not different based on genetic profile.
- | Tevimbra (tislelizumab-jsgr) / BeiGene, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment open, Real-world evidence, Real-world, Metastases: Triple Therapy for Intermediate-advanced HCC With BDTT (TALENP002) (clinicaltrials.gov) - Oct 15, 2024
P=N/A, N=20, Recruiting, Sponsor: Fujian Provincial Hospital
The time to treatment failure for lenvatinib was not different based on genetic profile. Not yet recruiting --> Recruiting
- | Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: Histology-specific clinical trial of lenvatinib and pembrolizumab in patients with sarcoma. (Pubmed Central) - Oct 15, 2024
Patients with UPS and angiosarcoma also responded. Further exploration of this approach is warranted to confirm activity and determine optimal dosing schedules.
- AiRuiKa (camrelizumab) / HLB Bio Group, Lenvima (lenvatinib) / Eisai, Merck (MSD)
CAMRELIZUMAB COMBINED WITH LENVATINIB AND RALOX-HAIC FOR HEPATOCELLULAR CARCINOMA (HCC) IN BCLC STAGE B AND C: A PROSPECTIVE, SINGLE-ARM TRIAL (CAL ERA STUDY) () - Oct 15, 2024 - Abstract #AASLD2024AASLD_3286;
P2
Combination treatment with camrelizumab and lenvatinib plus RALOX-HAIC showed promising antitumor activity and acceptable toxicity in patients with advanced HCC. The plasma proteins could serve as biomarkers to predict the curative effect of this combination treatment.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
LENVATINIB INHIBITS THE EFFICACY OF CHIMERIC ANTIGEN RECEPTOR MACROPHAGE (CAR-M) THERAPY IN TREATING HEPATOCELLULAR CARCINOMA () - Oct 15, 2024 - Abstract #AASLD2024AASLD_3254;
Therefore, in clinical trials of CAR-M therapy, a washout period should be considered after Lenvatinib usage. The impact of other tyrosine kinase inhibitors (TKIs) on CAR-M therapy should also be evaluated in future studies.
- Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
ASSOCIATION OF GENETIC ALTERATIONS WITH TREATMENT EFFICACY OF SYSTEMIC THERAPY FOR UNRESECTABLE HEPATOCELLULAR CARCINOMA: ANALYSIS WITH NATIONAL GENOMIC DATABASE IN JAPAN () - Oct 15, 2024 - Abstract #AASLD2024AASLD_3238;
Later treatment line was related to poor TTF in LEN and SOR. Further study is needed to validate these results.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
THE DUAL ROLE OF LET-7 MICRORNAS IN HEPATITIS C VIRUS-RELATED HEPATOCELLULAR CARCINOMA: A BIOMARKER FOR RISK STRATIFICATION AND A POTENTIAL THERAPEUTIC TARGET IN INFLAMMATION-DRIVEN CANCERS () - Oct 15, 2024 - Abstract #AASLD2024AASLD_3232;
We also show that HCV core protein downregulates let-7a/b expression in hepatoma cells, promoting cancer phenotypes and lenvatinib resistance, which can be reversed by let-7a/b overexpression. The mechanisms may involve modulation of cancer stem cell properties, apoptosis, and drug transporters.
- SURVIVAL AFTER REMOVAL FROM LIVER TRANSPLANT WAITLIST FOR HEPATOCELLULAR CARCINOMA PROGRESSION: EFFECTS OF IMMUNOTHERAPY AND THERAPY TYPE () - Oct 15, 2024 - Abstract #AASLD2024AASLD_2654;
Prognosis is generally poor; however, this cohort shows meaningful survival in a small group of patients beyond prior survival expectations. Optimum therapy of patients for HCC after delisting needs further study.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
SARCOPENIA IMPACTS TREATMENT TOLERANCE AND SURVIVAL OF PATIENTS WITH HEPATOCELLULAR CARCINOMA IN CIRRHOSIS () - Oct 15, 2024 - Abstract #AASLD2024AASLD_2646;
Weight-based administration of systemic treatment may increase the occurrence of adverse events and early treatment discontinuation. Risk stratification and dosing according to sarcopenia can prolong survival and avoid early adverse events.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
LIPOPHILIC STATIN INCREASES SENSITIVITY FOR LENVATINIB BY SUPPRESSING YAP/TAZ IN HEPATOCELLULAR CARCINOMA CELL LINES AND PATIENT-DERIVED ORGANOIDS () - Oct 15, 2024 - Abstract #AASLD2024AASLD_2641;
Increased protein expression of YAP/TAZ in HCC cell lines and organoid models is correlated with lenvatinib resistance. Atorvastatin enhances the anticancer efficacy of lenvatinib by interfering with YAP/TAZ expression in HCC cell lines and organoids.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
THE INVOLVEMENT OF MICRORNA-1297 IN LENVATINIB RESISTANCE IN HEPATOCELLULAR CARCINOMA CELLS () - Oct 15, 2024 - Abstract #AASLD2024AASLD_2631;
signaling through TMSB10. These observations indicate that microRNAs may represent an attractive target for overcoming lenvatinib resistance.
- Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
ATEZOLIZUMAB COMBINED WITH BEVACIZUMAB VERSUS SORAFENIB AND LENVATINIB FOR PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA: A SYSTEMIC REVIEW AND META-ANALYSIS FOR RANDOMIZED CONTROLLED TRIALS () - Oct 15, 2024 - Abstract #AASLD2024AASLD_2620;
ATEZO/BEV has better survival outcomes than Sorafenib and Lenvatinib and better safety than Lenvatinib in treating unresectable HCC. However, Lenvatinib might be an appropriate treatment option for patients with non-viral HCC.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
FUNCTIONAL ROLE OF MICRORNA-491 IN LENVATINIB RESISTANCE IN HEPATOCELLULAR CARCINOMA () - Oct 15, 2024 - Abstract #AASLD2024AASLD_2617;
miR-491 plays a role in hypoxia-induced lenvatinib resistance in HCC, and modulating its expression could partially restore lenvatinib cytotoxicity. These findings indicate the potential of targeting microRNAs to overcome lenvatinib resistance.
- Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
PERIPHERAL BLOOD INFLAMMATORY SCORE USING A CYTOKINE MULTIPLEX ASSAY PREDICTS CLINICAL OUTCOMES IN UNRESECTABLE HCC PATIENTS TREATED WITH ATEZOLIZUMAB/BEVACIZUMAB () - Oct 15, 2024 - Abstract #AASLD2024AASLD_2559;
These results suggest that the cytokine-multiplex assay-based scoring system significantly predicts clinical outcomes in AB-treated HCC patients. This non-invasive blood base biomarker needs to be validated in multicenter, large-sized cohorts.
- Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
FACTORS ASSOCIATED WITH TYPE OF FIRST-LINE TREATMENT RECEIVED FOR UNRESECTABLE HEPATOCELLULAR CARCINOMA IN THE ERA OF IMMUNOTHERAPY () - Oct 15, 2024 - Abstract #AASLD2024AASLD_2539;
Background: In 2020, the landscape of 1L therapy for unresectable hepatocellular carcinoma (uHCC) shifted with the approval of the first immunotherapy (IO), atezolizumab plus bevacizumab (A+B), replacing tyrosine kinase inhibitors (TKIs) as the standard of care... This was a retrospective cohort study of uHCC patients (pts) who received 1L therapy with A+B (A+B cohort), or sorafenib or lenvatinib (TKI cohort) between Jun 2020 and Jul 1, 2023, using nationwide Flatiron Health electronic health record (EHR)
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
MACHINE LEARNING RADIOMICS BASED ON CT TO PREDICT RESPONSE TO LENVATINIB PLUS PD-1 INHIBITOR FOR HEPATOCELLULAR CARCINOMA () - Oct 15, 2024 - Abstract #AASLD2024AASLD_2530;
Valuable clinical feature-based and radiomic feature-based models were constructed through ML algorithms to predict response to lenvatinib plus PD-1 inhibitor for uHCC. This shed new insight into developing new techniques to guide clinical decision making.
- Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
RISK OF BLEEDING IN HEPATOCELLULAR CARCINOMA PATIENTS TREATED WITH ATEZOLIZUMAB/BEVACIZUMAB: A SYSTEMATIC REVIEW AND META-ANALYSIS () - Oct 15, 2024 - Abstract #AASLD2024AASLD_2492;
Atezolizumab/ bevacizumab therapy for advanced HCC carries a heightened risk of gastrointestinal bleeding, exceeding that of tyrosine kinase inhibitors. High BMI and higher ALBI grade are key predictors of bleeding complications, emphasizing the need for cautious patient selection and monitoring.
- Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
HIGHER RISK OF PROTEINURIA IN ATEZOLIZUMAB PLUS BEVACIZUMAB THAN LENVATINIB AS A FIRST-LINE SYSTEMIC TREATMENT IN UNRESECTABLE HEPATOCELLULAR CARCINOMA () - Oct 15, 2024 - Abstract #AASLD2024AASLD_2481;
High BMI and higher ALBI grade are key predictors of bleeding complications, emphasizing the need for cautious patient selection and monitoring. Patients treated with Atezo/Bev as first-line systemic treatment for HCC exhibited a higher risk of proteinuria compared with those with LEN, particularly when accompanied by MVI.
- ||| SAL008 / Shenzhen Salubris
Enrollment closed, Monotherapy: Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer (clinicaltrials.gov) - Oct 15, 2024
P1/2, N=263, Active, not recruiting, Sponsor: Salubris Biotherapeutics Inc
Patients treated with Atezo/Bev as first-line systemic treatment for HCC exhibited a higher risk of proteinuria compared with those with LEN, particularly when accompanied by MVI. Recruiting --> Active, not recruiting
- ||||| Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Enrollment closed: IMbrave251: A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab (clinicaltrials.gov) - Oct 15, 2024
P3, N=554, Active, not recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: GOLM1 dictates acquired Lenvatinib resistance by a GOLM1-CSN5 positive feedback loop upon EGFR signaling activation in hepatocellular carcinoma. (Pubmed Central) - Oct 14, 2024
Finally, GOLM1 knockdown was found to act in synergy with Lenvatinib in subcutaneous and orthotopic mouse model. Overall, these findings identify a mechanism of resistance to Lenvatinib treatment for HCC, highlight an effective predictive biomarker of Lenvatinib response in HCC and show that targeting GOLM1 may improve the clinical benefit of Lenvatinib.
- | Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal, Checkpoint inhibition, Tumor mutational burden, PD(L)-1 Biomarker, IO biomarker: SMARCA4-deficient uterine tumors in young women: response to immune checkpoint inhibitors. (Pubmed Central) - Oct 14, 2024
This study presents the first report on the response to immune checkpoint inhibitor and multikinase inhibitor in SDUS. The online version contains supplementary material available at 10.1007/s13691-024-00721-2.
- | Kaitanni (cadonilimab) / Akesobio, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Retrospective data, Journal, Combination therapy, Real-world evidence, Real-world: Cadonilimab (PD-1/CTLA-4) in combination with lenvatinib in unresectable hepatocellular carcinoma (uHCC): A retrospective real-world study. (Pubmed Central) - Oct 14, 2024
The online version contains supplementary material available at 10.1007/s13691-024-00721-2. TRAEs of grade 3 or higher occurred in 51.7
- Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Lenvatinib/pembrolizumab combination therapies in metastatic G3 soft tissue sarcomas (Sydney) - Oct 13, 2024 - Abstract #DGHO2024DGHO_1536;
Follow up of the patients is between 5 and 20 months. The PFS is not reached but is beyond 17 months.
- Treatment reality and outcome of patients with intermediate, locally advanced or metastatic hepatocellular carcinoma - data from the prospective, national, intersectoral registry platform JADE (Geneva 1-2) - Oct 13, 2024 - Abstract #DGHO2024DGHO_1352;
P=N/A
ATZ+BEV was rapidly adopted as the new first-line standard of care for HCC followed by target inhibitor treatment in second-line (SOR > LEN). Patients in real-world setting are older, have more comorbidities, and more often have compromised liver function or impaired performance status at start of therapy compared to clinical trials which is reflected in the outcomes data.
- Lenvima (lenvatinib) / Eisai, Merck (MSD), Cabometyx (cabozantinib tablet) / Exelixis
Young Investigator Award: Tyrosine kinase inhibitors as sensitizers for CAR-T cell therapies in solid tumors (Rio) - Oct 13, 2024 - Abstract #DGHO2024DGHO_1206;
Among the used tyrosine kinase inhibitors, lenvatinib showed the most promising activation of immune pathways compared to cabozantinib and sorafenib... In summary, the addition of lenvatinib to ROR1 CAR Ts strongly improves CAR T-cell functionality, enhances the efficiency of CAR T-cells to kill tumour cells in vitro and in vivo , and blocks tumour metastasis by eradicating circulating tumour cells.
- Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Changes in prognosis and therapy for thyroid carcinoma in the pre-immunotherapy era (2010-2013) versus immunokinase inhibitor therapies (2019-2022) (Darwin) - Oct 13, 2024 - Abstract #DGHO2024DGHO_494;
Despite the unaltered high early mortality the long-term prognosis of patients with ATC has improved significantly and patients treated with immunecheckpoint/kinase inhibitor combinations can reach long-term survival over several years. Despite lack of phase III trials due to the rarity of this entity, a general approval of the kinase inhibitor/immune checkpoint inhibitor combination for ATC by the health insurance companies needs to be achieved to give patients a real survival chance.
- Cabometyx (cabozantinib tablet) / Exelixis
Chronic Limited Renal Thrombotic Microangiopathy and Podocytopathy Secondary to Cabozantinib () - Oct 12, 2024 - Abstract #KIDNEYWEEK2024KIDNEY_WEEK_5245;
He underwent treatment with Y-90 with some benefit, and was subsequently started on atezolizumab and bevacizumab...It was determined that cabozantinib was causing his worsening proteinuria and TMA with podocytopathy, and thus his treatment regimen has changed to lenvatinib and pembrolizumab...Cabozantinib inhibits angiogenesis, and in this manner, may disrupt vascular integrity in the kidneys, thus inducing TMA and podocyte injury [2]. Podocytopathy compromises the glomerular filtration barrier, causing a nephrotic syndrome type presentation in [3].This case thus illustrates the importance of vigilant monitoring for renal side effects in patients initiated on cabozantinib so this medication can be dose-adjusted or discontinued so as to prevent irreversible renal impairment..
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: Stereotactic body radiotherapy versus lenvatinib for hepatocellular carcinoma with portal vein tumor thrombosis: a propensity matching score analysis. (Pubmed Central) - Oct 12, 2024
Podocytopathy compromises the glomerular filtration barrier, causing a nephrotic syndrome type presentation in [3].This case thus illustrates the importance of vigilant monitoring for renal side effects in patients initiated on cabozantinib so this medication can be dose-adjusted or discontinued so as to prevent irreversible renal impairment.. In HCC patients with PVTT, SBRT had a better survival benefit than Lenvatinib treatment as first-line therapy.
- | Tevimbra (tislelizumab-jsgr) / BeiGene, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal, Metastases: A case report: deep and durable response to low-dose lenvatinib and tislelizumab in an elderly patient with advanced intrahepatic cholangiocarcinoma. (Pubmed Central) - Oct 11, 2024
The case provides valuable insights that could influence future treatment strategies for older patients with advanced cholangiocarcinoma who are unsuitable for chemotherapy. The dose-individualized chemotherapy-free regime of lenvatinib and tislelizumab might be used in similar cases to improve their outcomes.
- | Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD), Cabometyx (cabozantinib tablet) / Exelixis
Journal: Sudden Vision Loss in a Patient With Renal Cell Carcinoma: A Potential Indicator of Choroidal Metastasis. (Pubmed Central) - Oct 11, 2024
Consecutively, the therapy was switched to lenvatinib and pembrolizumab...Ophthalmologic examination in RCC patients experiencing sudden vision loss is essential to detect these specific metastases as soon as possible. Comprehensive documentation and awareness of these rare metastatic manifestations are essential to improving diagnostic accuracy and patient outcomes.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
BUDD-CHIARI SYNDROME AND HEPATOCELLULAR CARCINOMA: A CLINICAL QUANDARY () - Oct 11, 2024 - Abstract #ASCOMOS2024ASCOMOS_308;
Both her BCS and HCC is noted to be stable as evidenced by serial three monthly CT imaging and she was clinically asymptomatic, most importantly her quality of life is at optimum. CONCLUSION BCS associated HCC patient often present with complex clinical quandary which requires multidisciplinary approach in managing their condition without compromising their quality of life.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
LENVATINIB FOR TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA: EXPERIENCE IN A SINGLE INSTITUTION IN MALAYSIA () - Oct 11, 2024 - Abstract #ASCOMOS2024ASCOMOS_260;
CONCLUSION Despite Lenvatinib showing favorable efficacy and safety in multiple trials, more than half of the patients in our center experienced at least one AE that caused an interruption in treatment; 41.6% had discontinuation. Its toxicity remains a challenge for us in terms of management in real-world practice.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
TREATMENT RELATED POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME IN CANCER PATIENTS () - Oct 11, 2024 - Abstract #ASCOMOS2024ASCOMOS_256;
lady with metastatic hepatocellular carcinoma was started Lenvatinib in Feb 2024...Case Report 2 54 y.o. lady, diagnosed metastatic rectosigmoid colon carcinoma, was treated with Oxaliplatin + Capecitabine...With new neurological symptoms during cancer treatment, PRES should be suspected and confirmation through MRI. PRES is often reversible with early recognition and removal of causative agent.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
ERYTHROCYTOSIS: A RARE BUT DISTINCTIVE COMPLICATIONS IN HEPATOCELLULAR CARCINOMA PATIENTS TREATED WITH LENVATINIB () - Oct 11, 2024 - Abstract #ASCOMOS2024ASCOMOS_224;
His blood parameters returns to baseline with temporary withdrawal of lenvatinib which further supported our clinical diagnosis. CONCLUSION In conclusion, erythrocytosis a potentially rare but distinctive complication in hcc patients receiving lenvatinib that warrants high clinical suspicion and close clinical monitoring in this group of patients.
- 5-fluorouracil / Generic mfg.
CHEMOTHERAPY: THE UNLIKELY HERO IN OVERCOMING HCC RESISTANCE. A CASE REPORT () - Oct 11, 2024 - Abstract #ASCOMOS2024ASCOMOS_217;
However, after 3 cycles of Lenvatinib, her AFP persistently increased, leading to a switch to Atezolizumab-Bevacizumab...The shift to FOLFOX chemotherapy post-prior treatment failure, highlights the need of flexibility in patient care. Essentially, this and showcases the importance of personalized approach to optimize patient outcome.
- Kisqali (ribociclib) / Novartis, Lenvima (lenvatinib) / Eisai, Merck (MSD)
AMICABLE RESPONSE IN COMBINING SYSTEMIC THERAPIES AND SELECTIVE INTERNAL RADIATION THERAPY (SIRT) IN INOPERABLE PRIMARY AND SECONDARY LIVER TUMOURS: CASE SERIES (FOYER AREA) - Oct 11, 2024 - Abstract #ASCOMOS2024ASCOMOS_194;
None of these patients demonstrated significant adverse events, Common Terminology Criteria for Adverse Events (CTCAE) < 3. CONCLUSION In conclusion, these cases illustrate the potential role of combining systemic therapies with SIRT, which could be explored in future clinical trials.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: A MYC-STAMBPL1-TOE1 positive feedback loop mediates EGFR stability in hepatocellular carcinoma. (Pubmed Central) - Oct 10, 2024
Inhibition of STAMBPL1 or TOE1 synergistically improves the antitumor activity of lenvatinib. Our work shows the mechanism of STAMBPL1 in liver cancer and suggests it as a potential therapeutic target for liver cancer treatment.
- ||||||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion, Metastases: Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002) (clinicaltrials.gov) - Oct 10, 2024
P3, N=794, Completed, Sponsor: Merck Sharp & Dohme LLC
Our work shows the mechanism of STAMBPL1 in liver cancer and suggests it as a potential therapeutic target for liver cancer treatment. Active, not recruiting --> Completed
- ||| E7386 / Eisai, PRISM Pharma
Phase classification, Enrollment change, Trial completion date, Trial primary completion date: E7386-J081-102: A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor (clinicaltrials.gov) - Oct 8, 2024
P1/2, N=301, Recruiting, Sponsor: Eisai Inc.
Active, not recruiting --> Completed Phase classification: P1 --> P1/2 | N=181 --> 301 | Trial completion date: Mar 2027 --> Nov 2026 | Trial primary completion date: Mar 2027 --> Nov 2026
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
New trial, Combination therapy, Metastases: HAIC in Combination with PD-1 Inhibitors and Lenvatinib for Intermediate and Advanced HCC After the Failure of Systemic Therapy Recommended by BCLC (clinicaltrials.gov) - Oct 8, 2024
P=N/A, N=84, Recruiting, Sponsor: First Hospital of China Medical University
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
New trial, Combination therapy, Metastases: HAIC in Combination with PD-1 Inhibitors and Lenvatinib for High Tumor Burden Advanced HCC (CHANCE2416) (clinicaltrials.gov) - Oct 7, 2024
P=N/A, N=228, Recruiting, Sponsor: First Hospital of China Medical University
- | Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
Journal, Metastases: Current status of the cost burden of first-line systemic treatment for patients with advanced hepatocellular carcinoma in Japan, 2021-22. (Pubmed Central) - Oct 7, 2024
Advances in systemic therapies for HCC have led to prolonged patient survival. However, the treatment costs are also increasing, imposing a burden on both the patients and society.
- | Journal, PD(L)-1 Biomarker, Metastases: KL-6 Mucin as Serum Tumor Marker of Metastatic Renal Cancer: A Case Report. (Pubmed Central) - Oct 7, 2024
He started treatment with lenvatinib and pembrolizumab...He discontinued axitinib in November. KL-6 increased to 29640?U/mL in December.
- || Lenvima (lenvatinib) / Eisai, Merck (MSD)
Review, Journal, Combination therapy: Combination therapy consisting of transarterial chemoembolization, lenvatinib, and programmed cell death protein 1 blockade for hepatocellular carcinoma with inferior vena cava tumor thrombus: a case series study and literature review. (Pubmed Central) - Oct 6, 2024
KL-6 increased to 29640?U/mL in December. The combination of TACE, lenvatinib, and PD-1 is effective for HCC with IVCTT and has acceptable adverse effects.